AI assistant
Beta Bionics, Inc. — Director's Dealing 2025
Aug 21, 2025
32351_dirs_2025-08-20_39fd7dca-a0df-4319-8d84-0283650a39e5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Beta Bionics, Inc. (BBNX)
CIK: 0001674632
Period of Report: 2025-08-19
Reporting Person: Hopman Mark (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-08-19 | Common Stock | M | 16158 | $5.10 | Acquired | 50290 | Direct |
| 2025-08-19 | Common Stock | S | 16158 | $16.6095 | Disposed | 34132 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-08-19 | Employee Stock Option (right to buy) | $5.10 | M | 16158 | Disposed | 2033-07-26 | Common Stock (16158) | Direct |
Footnotes
F1: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 13, 2025.
F2: The weighted average sale price for the transaction reported was $16.6095 and the range of prices were between $16.26 and $17.1719. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F3: One-fourth of the shares subject to this option shall vest one year after March 20, 2023, and thereafter 1/36th of the shares subject to this option shall vest on each monthly anniversary thereof.